Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
17/09/2020
A MULTI-CENTRE, OPEN-LABEL PHASE 2 TRIAL OF THE COMBINATION OF VB10.16 AND ATEZOLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT, NON-RESECTABLE HPV16 POSITIVE CERVICAL CANCER
19/03/2020
UPDATE FROM VACCIBODY’S CLINICAL TRIAL WITH THE PERSONALIZED CANCER NEOANTIGEN VACCINE, VB10.NEO | San Diego, March 2020
18/11/2019
POSTER FROM THE 21ST EUROPPEAN CONGRESS ON GYNAECOLOGICAL ONCOLOGY | Athens, November 2019.
09/11/2019
VB10.NEO, AN INDIVIDUALIZED NEOEPITOPE CANCER VACCINE, INDUCES POSITIVE CLINICAL RESPONSES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOURS | Maryland, November 2019
16/10/2019
CONSIDERATIONS AND EXPERIENCES FROM TAKING A FULLY PERSONALIZED TARGETED CANCER NEOANTIGEN DNA VACCINE INTO THE CLINIC | London, October 2019
Pages:
1
2
3
4
5
6
7
8
9
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
